Your browser doesn't support javascript.
loading
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono, Paola; Tocci, Annalisa; Palermo, Belinda; Di Carlo, Anna; D'Ambrosio, Lorenzo; D'Andrea, Daniel; Di Modugno, Francesca; De Nicola, Francesca; Goeman, Frauke; Corleone, Giacomo; Warren, Sarah; Paolini, Francesca; Panetta, Mariangela; Sperduti, Isabella; Baldari, Silvia; Visca, Paolo; Carpano, Silvia; Cappuzzo, Federico; Russo, Vincenzo; Tripodo, Claudio; Zucali, Paolo; Gregorc, Vanesa; Marchesi, Federica; Nistico, Paola.
  • Trono P; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy paola.nistico@ifo.it paola.trono@cnr.it.
  • Tocci A; Institute of Biochemistry and Cell Biology, Consiglio Nazionale delle Ricerche, Rome, Italy.
  • Palermo B; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Di Carlo A; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • D'Ambrosio L; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • D'Andrea D; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Di Modugno F; Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
  • De Nicola F; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Goeman F; SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Corleone G; SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Warren S; SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Paolini F; NanoString Technologies Inc, Seattle, Washington, USA.
  • Panetta M; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Sperduti I; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Baldari S; Biostatistics Unit, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
  • Visca P; Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Carpano S; Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Cappuzzo F; Second Division of Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Russo V; Second Division of Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Tripodo C; Department of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Zucali P; Department of Health Sciences, Human Pathology Section, Tumor Immunology Unit, University of Palermo, Palermo, Italy.
  • Gregorc V; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Marchesi F; Department of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Nistico P; Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
J Immunother Cancer ; 11(8)2023 08.
Article en En | MEDLINE | ID: mdl-37612043
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article